660
Participants
Start Date
September 7, 2023
Primary Completion Date
November 15, 2023
Study Completion Date
May 20, 2024
XBB.1.5 Vaccine (Booster)
Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine (Booster)
XBB.1.5 Vaccine (single dose)
Omicron sub variant XBB.1.5 SARS-CoV-2 rS /Matrix-M Adjuvant the monovalent \[5 μg/50 μg\] NVX-CoV2601) XBB.1.5 Vaccine ( single dose)
Rochester Clinical Research, Rochester
DM Clinical Research, Philadelphia
University of Maryland, Baltimore
Health Research of Hampton Roads, Newport News
Tekton Research, Lawrenceville
AMR LLC-Miami, Coral Gables
Health Awareness,LLC, Jupiter
AMR, Fort Myers
AMR, Mobile
AMR, Knoxville
Sundance Clinical Research, St Louis
AMR, Kansas City
Alliance for Multispecialty RSCH, Newton
Tekton Research, Wichita
Velocity Clinical Research, Norfolk
AMR New Orleans, New Orleans
Tekton Research, Yukon
Research For Your Health, Plano
Benchmark Research, Fort Worth
Tekton Research, Beaumont
Tekton Research, San Antonio
Pan American clinical Research,LLC, Brownsville
Benchmark Research, Austin
Tekton Research, Austin
Lynn Institute of the Rockies, Colorado Springs
AMR Layton Research Centre, Layton
AXCES Research, Albuquerque
AMR, Las Vegas
Benchmark Research, Sacramento
University of Washington, Seattle
Lead Sponsor
Novavax
INDUSTRY